Next Article in Journal
Convection Enhanced Delivery in the Setting of High-Grade Gliomas
Next Article in Special Issue
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States
Previous Article in Journal
Topical Antiseptic Formulations for Skin and Soft Tissue Infections
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 4
10.3390/pharmaceutics13040559
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents

by
Jaeok Lee
1,†,
Jiyeon Kang
1,†,
Na-Yun Kwon
1,
Aneesh Sivaraman
2,
Ravi Naik
2,
So-Young Jin
1,
A. Reum Oh
1,
Jae-Ho Shin
3,
Younghwa Na
3,
Kyeong Lee
2 and
Hwa-Jeong Lee
1,*
1
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
2
College of Pharmacy, Dongguk University, Goyang-si 10326, Korea
3
College of Pharmacy, CHA University, Pocheon-si 11160, Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to the work.
Pharmaceutics 2021, 13(4), 559; https://doi.org/10.3390/pharmaceutics13040559
Submission received: 12 March 2021 / Revised: 12 April 2021 / Accepted: 13 April 2021 / Published: 15 April 2021
(This article belongs to the Special Issue Drug Delivery Systems for Oral Immunotherapy)
Browse Figures
Versions Notes

Abstract

:
P-glycoprotein (P-gp) inhibition has been studied to overcome multidrug resistance in cancer chemotherapy but failed in clinical trials due to low/toxic effects. Recently, a dual modulation of transporters and natural derivatives have been examined to surmount this limitation. We examined breast cancer resistance protein (BCRP) inhibition in vitro and in vivo by P-gp inhibitors derived from natural compounds in previous studies. P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)—a substrate of P-gp and BCRP, albeit with higher affinity for BCRP—in BCRP-overexpressing cells, resulting in cell death. These dual inhibitors, when orally co-administered with TPT, enhanced TPT bioavailability with slightly reduced total oral clearance (Clt/F) in rats. In xenograft mice, they strengthened oral TPT-induced tumor reduction with no alterations in body weight. Moreover, we investigated the effects of an oral drug formulation (Cremophor® EL, Tween® 80, and polyethylene glycol 400) on the transporters function. The excipients increased TPT accumulation in P-gp- or BCRP-overexpressing cells. Oral TPT bioavailability was higher with the formulation than with a control, as shown by the increases in the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve from zero to infinity (AUCINF) (p < 0.01). Therefore, oral TPT bioavailability was enhanced by P-gp/BCRP dual inhibition, which resulted in a formulation-mediated increase in absorption and decrease in elimination, and a dual inhibitor-mediated decrease in elimination. These results suggest that the combination of dual inhibition by a natural derivative and the drug formulation can be a useful clinical approach.

Graphical Abstract

1. Introduction

Adenosine triphosphate (ATP)-binding cassette (ABC) transporters belong to one of the largest transporter families and act as active ATP-dependent efflux pumps in living organisms [1,2]. The function of these ABC transporters is intimately associated with multidrug resistance (MDR) in cancer treatment [3]. P-glycoprotein (P-gp)—ABC subfamily B member 1 (ABCB1)—is a well-characterized MDR transporter, and was the first transporter to be identified [4]. Breast cancer resistance protein (BCRP)—ABCG2—is also a crucial MDR transporter and is a recently identified and less-characterized transporter among the ABC transporters [5]. P-gp and BCRP are related not only to pathogenic conditions, but also to normal physiological roles. They are widely expressed in important tissues such as the intestinal epithelium, the biliary canaliculi of hepatocytes, the proximal tubules of kidney, and the endothelium at the blood–brain barrier (BBB) [6]. Although both transporters have different sizes, structures, and domain arrangement [3,7], many anticancer drugs have been discovered from their common substrates [8,9].
In addition, ABC transporters strongly influence the absorption, distribution, metabolism, and excretion of drugs [10]. Therefore, the United States Food and Drug Administration (US-FDA) has formulated guidelines for the evaluation of P-gp- and BCRP-mediated drug interactions [11]. Because efflux transporters are the one of the primary causes of MDR and restricted BBB penetration, and can alter the pharmacokinetic (PK) properties of various anticancer drugs, their modulation has been of interest in addressing MDR, BBB penetration, and improving the oral bioavailability (BA) of substrate drugs [12,13]. Most studies of transporter modulation have focused on single transporters [14,15]. Numerous studies have investigated P-gp modulation by molecules beyond the third generation of inhibitors, which have a high specificity and a low risk of adverse reactions, but show a lack of significant effects or unexpected toxicity in clinical trials [14,16]. Recently, a fourth generation of P-gp inhibitors using natural compounds or their derivatives and P-gp/BCRP dual-target modulation have been proposed for clinical investigation [16,17,18].
Meanwhile, many studies have focused on the interaction of excipients, such as surfactants present in oral drug formulations, with P-gp and BCRP [19,20]. Cremophor® EL, Tween® 80, and polyethylene glycol (PEG) 400 are typical nonionic surfactants and excipients whose effects have been investigated on P-gp or BCRP modulation [19]. Cremophor® EL increased the accumulation of P-gp or BCRP substrate drugs, such as daunorubicin (DNR) and mitoxantrone (MX), and Tween® 80 and PEG 400 also enhanced the accumulation of P-gp substrate drugs (Rh123, epirubicin) in different cell lines such as R100, Caco-2, and MDCK1 [19]. According to these reports, the proper use of excipients in the formulation of P-gp and BCRP substrate anticancer drugs would be a potent strategy for the enhancement of oral BA. However, preclinical evidence for the effects of excipients on P-gp or BCRP modulation is still limited because most evidence is based on in vitro studies. Moreover, the effect on P-gp and BCRP dual modulation has not been studied yet to our knowledge.
Topotecan (TPT), a water-soluble camptothecin analog that inhibits the catalytic activity of DNA topoisomerase I, is a widely used anticancer drug against various cancers, including ovarian, lung, and other cancers [21]. TPT is administered through the intravenous (IV) and per oral (PO) routes [21]. Under physiological pH, TPT is unstable because its lactone moiety is converted to a carboxylated open-ring form, which has low topoisomerase I inhibitory activity [22]. In humans, the oral BA of active TPT is reported to be approximately 35%. It is eliminated by both renal excretion (approximately 40% of the total administered dose) and hepatic metabolism (low amount of N-desmethyl TPT (<7% of the total amount), which is most likely metabolized by cytochrome P450 3A (CYP3A)) with a half-life of 3 h [22]. This anticancer drug is classified as a substrate of P-gp and BCRP transporters, with a higher affinity for BCRP [8,9,23]. Therefore, the inhibition of both transporters during TPT treatment has been proposed to enhance oral BA and BBB penetration, as well as for reversing MDR. Few studies have investigated this dual inhibition [23,24,25,26].
Previously, our studies have investigated P-gp modulation with numerous derivatives of natural compounds, including coumarin derivatives, optically active phenylbutenoid dimers, xanthone analogues, benzoxanthone analogues, piperazine derivatives, and ferulic acid derivatives [27,28,29,30,31,32]. Here, we assessed P-gp and BCRP dual-modulatory activity with some P-gp modulators from our previously reported series of natural compound derivatives [27,29,30] to confirm the possibility that P-gp modulators could be developed as P-gp/BCRP dual-target modulators—another concept of fourth generation modulation. Among the selected compounds, compounds 2 [30], LL344 [27], and 13-1 (modified from xanthone analogue 13 [29]) (Figure S1), increased the oral BA of TPT, a substrate of both transporters, in rats, and enhanced tumor growth reduction in human colon cancer cell xenograft-bearing nude mice when co-administered orally with TPT. Moreover, we demonstrated that the modified Taxol® formulation containing Cremophor® EL, Tween® 80, and PEG 400 had dual modulatory activity by improving oral TPT absorption in these animals.

2. Materials and Methods

2.1. Materials

P-gp and BCRP dual inhibitor candidates (approximately 99% purity) were synthesized by K. Lee [27] and Y. Na [30]. TPT, mitoxantrone (MX), and DNR were purchased from Mesochem (Beijing Mesochem Technology Co., Ltd., Beijing, China). Zosuquidar (MedChemExpress, Monmouth Junction, NJ, USA), Ko143 (Abcam, Cambridge, UK), radioimmunoprecipitation assay (RIPA) buffer (CellNest, Tokoy, Japan), protease inhibitor (Calbiochem, San Diego, CA, USA), and antibodies against P-gp (C219, Enzo life sciences AG., Lausen, Switzerland), BCRP (BXP21, Santa Cruz Biotechnology, Inc., CA, USA), β-actin (C4, Santa Cruz Biotechnology, Inc., CA, USA), and goat anti-mouse IgG horseradish peroxidase-conjugated antibody (EMD Millipore, Billerica, MA, USA) were commercially obtained. Cremophor® EL, Tween® 80, PEG 400, dimethylsulfoxide (DMSO), and acridine were purchased from Sigma-Aldrich (Millipore Sigma Co., Burlington, MA, USA). Zoletil 50 (Virbac S.A., Carros, France, USA), Rumpun® injection (Bayer Korea, Seoul, Korea), isoflurane (Hana Pharm Co., Ltd., Seoul, Korea), heparin sodium injections (Joongwae Pharm., Seoul, Korea), and Matrigel® (Corning®, Corning, NY, USA) were purchased. All reagents and solvents were of molecular biology and cell culture grades, animal experiment grade, or high-performance liquid chromatography (HPLC) analysis grade.
The human breast cancer cell lines MCF-7, MCF-7/ADR (P-gp-overexpressing), and MCF-7/MX100 (BCRP-overexpressing) were kindly gifted by Marilyn E. Morris (University of Buffalo, NY, USA), and the human colorectal cancer cell line, HT29, was presented by U. Schumacher (University Medical Center of Hamburg-Eppendorf, Hamburg, Germany). Laboratory animals, Sprague–Dawley (SD) rats and Balb/c nude mice, were purchased from Orient Bio (Seongnam, Korea).

2.2. Cell Culture

Parental, MCF-7/ADR, and MCF-7/MX100 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) media, DMEM containing 1 μM doxorubicin, and DMEM containing 0.1 μM MX, respectively, and HT29 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 media at 37 °C in a humidified 5% CO2 atmosphere. DMEM media were supplemented with 25 mM D-glucose, 4 mM L-glutamine, 1 mM sodium pyruvate, 44 mM NaHCO3, and 10% fetal bovine serum, and RPMI 1640 media were supplemented with 2 mM L-glutamine, 0.1 mM L-methionine, 24 mM NaHCO3, and 10% fetal bovine serum.

2.3. Western Blotting Analysis

MCF-7/ADR and MCF-7/MX100 cells incubated with P-gp and BCRP dual inhibitor candidates for 48 h were lysed and sonicated in RIPA buffer containing a protease inhibitor cocktail. Fifty micrograms of each protein sample were electrophoretically separated in a 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel under reducing conditions, followed by transfer to an activated polyvinyldifluoride membrane. After blocking with 5% skimmed milk solution, the membrane was incubated overnight with primary antibodies against P-gp (1:250), BCRP (1:100), and β-actin (1:2000) at 4 ℃. This was followed by incubation with the secondary antibody (1:2000‒1:10,000). The horseradish peroxidase reaction for the detection of target protein expression levels was monitored using a ChemiDOC MP (Universal Hood III #731BR02006, Bio-Rad Laboratory, USA), and target protein levels were measured with ImageJ software (version 1.52n, NIH, Bethesda, MD, USA). Three independent experiments were analyzed.

2.4. Cell Survival Study

MCF-7/ADR and MCF-7/MX100 cells (9 × 103/well) in 96-well plates were incubated with TPT with or without dual inhibitor candidates for 48 h. Cell survival was examined using the sulforhodamine B staining assay [33]. Absorbance was measured at 515 nm with a spectrophotometer (Multiskan GO with Cuvette function #1510-04234, Thermo Fisher Scientific, Vartaa, Finland). The assay was performed at least in triplicate.

2.5. Substrate Drug Accumulation Study by Flow Cytometry

The trypsinized cells (1 × 106‒3 × 106) were incubated in prewarmed phenol red-free media (500 μL) with 200 μM TPT with or without zosuquidar, Ko143, each dual inhibitor candidate, Cremophor® EL, Tween® 80, and PEG 400 for 30 min, or with 10 μM DNR in the presence and absence of compound 13-1 for 30 min at 37 ℃, after washing with media through a 26 G syringe needle. In this study, the cells were treated with TPT or DNR after incubation with the P-gp and/or BCRP inhibitor candidates or with the excipients for 5 min. When the incubation was complete, the medium containing the substrate and inhibitor candidate or excipient was removed, and the cells were resuspended in cold phosphate buffer saline (PBS) (500 μL). TPT accumulation in the cells was measured using a flow cytometer (NovoCyte 2060R, ACEA Biosciences Inc., San Diego, CA, USA). The mean fluorescence intensity values were calculated, and at least three independent biological duplicates were performed.

2.6. Animal Experiments

All animal experiments were performed as per the procedures approved by the Ewha Womans University Institutional Animal Care and Use Committee (IACUC), Korea (No. 2019-19-002 approved on 11 January 2019 for the pharmacokinetic study, No. 2016-16-062 approved on 7 December 2016, and No. 2018-18-072 approved on 29 December 2018 for the xenograft study).

2.6.1. Pharmacokinetic (PK) Studies

Drug Formulations

TPT at 2 mg/mL was prepared immediately prior to use using the modified Taxol® formulation (Cremophor® EL, PEG 400, Tween® 80, and an isotonic saline solution (25/5/0.5/69.5, v/v/v/v) mixed with DMSO (9:1, v/v)). Compounds 2, 3, LL344, LL347, and 13-1 (Figure S1) were dissolved in DMSO at concentrations of 2 mg/mL for PK studies in rats and 4 mg/mL for xenograft studies in mice. Each compound dissolved in DMSO was mixed with TPT in the modified Taxol® formulation without DMSO for oral administration to rats and mice.

Oral Administration and Plasma Sampling

For PK studies, the carotid artery in healthy SD rats (male, 7‒8 weeks, 220‒298 g) was catheterized one day before drug administration [29,30,31,32]. Four to six rats were grouped for the oral administration of TPT (20 mg/kg) with or without compounds (2 mg/kg) in the modified Taxol® formulation and the same dose of TPT in saline only. After drug administration, blood (approximately 250 μL) was sampled from the catheter at 0, 0.05, 0.12, 0.25, 0.5, 1, 2, 3, 4, 6, 10, and 24 h, and an equal volume of heparinized saline was refilled through the catheter to maintain total blood volume and prevent blood clotting. Plasma samples separated by centrifugation of blood at 13,000 rpm for 15 min at 4 ℃ were stored at −20 ℃ or −70 ℃ until analysis.

High Performance Liquid Chromatography-Fluorescence (HPLC-FC) Analysis

TPT concentrations in rat plasma were analyzed using an Agilent 1260 infinity system (Agilent Technology Inc., Waldbronn, Germany) equipped with Agilent ChemStation software (version Rev.B.04.03-SP2 (105), Agilent, Santa Clara, CA, USA), a quaternary pump, a degasser, a thermostatic autosampler, a thermostatic column compartment, and a fluorescence detector. The samples were chromatographically separated using a Capcell Pak C18 UG120 column (4.6 mm × 250 mm, 5 μm, Osaka Soda Co. Ltd., Osaka, Japan) with the mobile phase composed of 10 mM phosphate buffer containing 1% triethylamine (TEA) (pH 3.5) and methanol containing 1% TEA (pH 6.5) (56/44, v/v) at a flow rate of 1.0 mL/min for 30 min and detected at an excitation wavelength of 381 nm and an emission wavelength of 527 nm. The injection volume was 50 μL. The HPLC-FC method was validated according to US-FDA guidelines [34] as follows: specificity (TPT: 3.8 min; internal standard (IS): 18.1 min), linearity over the concentration range between 0.025 and 5.0 μg/mL (y = 0.2679x + 0.0013, coefficient of determination (r2) = 0.9997), lower limit of quantification (0.025 μg/mL), intra-/inter-day precision and accuracy (3.7–12.2% and 91.3–112.6%, respectively), and the short term, long term, freeze-thaw, and post-preparation stability of TPT (between 87.0% and 102.0%), and extraction recovery of TPT and IS (between 91.21% and 94.24%).
For the HPLC-FC analysis, TPT samples in rat plasma were prepared as follows: 33 μL plasma was mixed with 3 μL acridine (IS) (22.2 μg/mL), and the mixture was deproteinized with 84 μL cold methanol and 30 μL 100 mM phosphoric acid. The plasma sample was ready to inject after vertexing for 2 min, and then centrifuging at 13,000 rpm for 15 min.

PK Analysis

Pheonix WinNonlin® software (version 8.1, Pharsight Corporation, Mountain View, CA, USA) was used to estimate the PK parameters following oral TPT administration to rats. Non-compartmental analysis was performed using the plasma TPT concentration–time profiles to obtain the following PK parameters: area under the plasma concentration–time curve from zero to infinity (AUCINF), elimination half-life (t1/2), apparent volume of distribution after oral administration (Vd/F), and total oral clearance (Clt/F). The maximum plasma concentration (Cmax) and the time required to reach Cmax (Tmax) were directly measured from the plasma TPT concentration–time curve. The relative BA (RB) of TPT was calculated using the Equation (1):
RB (%) = (AUCINF po co-administration)/(AUCINF po control) × 100

2.6.2. Xenograft Trial

HT29 cells (3.5 × 106 in 50 µL Dulbecco’s phosphate-buffered saline–Matrigel® mixture (1:1)), expressing both P-gp and BCRP proteins endogenously, were subcutaneously inoculated into the flanks of Balb/c nude mice (male, 5-week, 18‒20 g). TPT (1 mg/kg) with or without inhibitor candidates (2 mg/kg), and the combination of zosuquidar and Ko143 (2 mg/kg each) versus the control (the modified Taxol® formulation itself) were orally administered twice weekly for 3‒3.5 weeks when the tumor volume reached approximately 100 mm3 (n = 5‒7/group). In this study, the inhibitor candidates and the positive control were administered 30 min before TPT treatment. The mouse tumor volume was measured with digital calipers, and body weight was monitored twice a week. The mice were euthanized when the tumor volume reached 2000 mm3 or in case of any signs of distress.

2.7. Statistical Analysis

Tukey’s honestly significant difference or Dunnett’s T3 test in conjunction with one-way ANOVA (Free GraphPad Prism, version 8.3.0, La Jolla, CA, USA) was used for the statistical analysis of Western blotting data, cell survival data, TPT accumulation data, and PK analyses of TPT with the inhibitor candidates. Student’s t-test/F-test, repeated-measures one-way ANOVA, and the Mann–Whitney U test (GraphPad Prism, version 8.3.0) were performed for the analysis of the effects on DNR accumulation of compound 13-1 and on tumor xenograft growth, and the PK of TPT in saline vs. the modified Taxol® formulation, respectively. PK parameters were represented as mean ± standard deviation (S.D.), and other data were represented as mean ± standard error of the mean (S.E.M.). Statistical significance was represented by p values < 0.05.

3. Results

3.1. Effects of P-gp Inhibitors on BCRP In Vitro

To determine whether the previously reported P-gp inhibitors could inhibit BCRP, we examined the effects of specific inhibitors on P-gp and BCRP function by monitoring TPT accumulation in P-gp- and BCRP-overexpressing cells (Figure 1). Compared to the parental cells, MCF-7/ADR and MCF-7/MX100 cells showed approximately 25-fold and 18-fold higher expression of P-gp and BCRP, respectively (Figure 1A). We observed over two-fold accumulation of TPT in MX100 cells (p < 0.01) when BCRP function was inhibited by its specific inhibitor (Ko143) compared with TPT-only treatment (Figure 1B). However, no significant difference was observed in TPT accumulation in ADR cells treated with a P-gp specific inhibitor (zosuquidar). P-gp function in ADR cells was confirmed with the accumulation of daunorubicin (DNR), a well-known P-gp substrate (Figure S2A). The P-gp specific inhibitor, zosuquidar, induced an approximately three-fold increase in DNR accumulation (versus 10 μM DNR-only control, p < 0.05). However, no significance difference was observed in TPT accumulation in the case of the combination treatment with P-gp- and BCRP-specific inhibitors compared to that observed separately for the inhibition of each transporter in both cell lines. Thus, these results demonstrate the suitability of this in vitro system for the subsequent experiments and confirm the higher affinity of TPT for BCRP in the present in vitro system.
The P-gp inhibitors, compounds 2, 3 [30], LL344, LL347 [27], and 13-1 (modified xanthone analog 13 [29]) were examined for their potential as BCRP inhibitors in the in vitro system described above (Figure 2). Owing to its effect on DNR accumulation, we confirmed the inhibitory activity of compound 13-1 toward P-gp efflux (Figure 2A). The compound increased DNR accumulation by approximately 2.5-fold in P-gp-overexpressing cells compared to the DNR-only control (p < 0.05). All compounds, confirmed to be P-gp inhibitors in vitro, were investigated for the inhibition of BCRP-mediated efflux activity through the analysis of TPT accumulation (Figure 2B). Compounds 2 and 3 significantly induced drug accumulation in MX100 cells (p < 0.05 and p < 0.01, respectively) to levels that were comparable to that observed for the specific BCRP inhibitor (Ko143) (Figure 1B). Compounds LL347 and 13-1 showed an increase in TPT accumulation in BCRP-overexpressing cells. Moreover, compound 2 significantly increased TPT accumulation in P-gp-overexpressing cells (p < 0.05). Because TPT accumulation in the cells after short-term incubation (up to 2 h) was much lower than that observed for other drugs (Figure S2B), the duration of incubation was increased to 48 h (Figure 2C). All compounds significantly increased TPT cytotoxicity versus the TPT-only control in BCRP-overexpressing cells (p < 0.01–0.0001) after co-treatment with 0.05 μM TPT, a non-toxic concentration of TPT. Increased TPT cytotoxicity was observed in P-gp-overexpressing cells after treatment with the P-gp inhibitors, except for compound 13-1, with significant cytotoxicity being observed for compounds 2 and LL347 versus the TPT-only control (p < 0.05). However, there were no significant changes in the protein levels of both efflux transporters after treatment with the compounds (Figure 2D).

3.2. Effects of Dual Inhibitor Candidates In Vivo: Pharmacokinetics (PK) of TPT Following Oral Co-Administration

Compounds whose dual inhibition of P-gp and BCRP had been confirmed in vitro were investigated for their inhibitory effects in our animal model. TPT (20 mg/kg) dissolved in the modified Taxol® formulation containing Cremophor® EL, PEG 400, Tween® 80, and isotonic saline solution mixed with DMSO (9:1, v/v) was orally administered to rats with or without each compound (2 mg/kg). Figure 3 and Table 1 show the mean plasma concentration–time profiles and PK parameters of TPT, respectively. In spite of the lack of statistical significance, all the compounds increased the AUCINF of TPT by approximately 1.4- to 2.0-fold, with a moderate decrease in Clt/F. Compound 2 exhibited the most prominent effects in the in vitro study (Figure 2B,C), where it demonstrated 1.6- and 2.1-fold increases in the Cmax and RB of TPT, respectively, whereas compound 13-1 demonstrated approximately 2.0-fold increase in the RB of TPT compared to TPT only (Figure 3 and Table 1). In addition, the Tmax of TPT was similar in the presence or absence of the compounds, and the second peak was monitored in the plasma TPT concentration–time profile after co-administration with compounds LL344 (4 h) and LL347 (6 h) (Figure 3).

3.3. Effects of Dual Inhibitor Candidates In Vivo: Tumor Growth after Oral Co-Administration with TPT

To evaluate the effects of the dual inhibitors on tumor growth, each compound (2 mg/kg) was orally co-administered with TPT (1 mg/kg) to tumor xenograft bearing mice, and the tumor volume and body weight of the mice were monitored on predetermined days (Figure 4). We generated the tumor xenograft model with human colon cancer cells (HT29) which endogenously express both P-gp and BCRP proteins [35] (Figure S3A), as P-gp and BCRP are expressed in the small intestine and colon [36]. The effects of orally administering the low dose of the dual inhibitor candidates (2 mg/kg) with the low dose of TPT (1 mg/kg) on tumor growth was investigated after confirming TPT sensitivity in HT29 cells (Figure S3B). At the end point, all compounds co-administered with TPT (multiple dosing) showed markedly smaller tumor volumes than the TPT-only group and the vehicle-treated control group (Figure 4A,B). Except for compound LL344, all the dual inhibitors significantly induced tumor reduction by TPT, compared to TPT only and the formulation only control (control vs. compound 2, p < 0.05; control vs. compound 3, p < 0.05; control vs. compound LL347, p < 0.05; control vs. compound 13-1, p < 0.05; TPT vs. compound 2, p < 0.05; TPT vs. compound 3, p < 0.01; TPT vs. compound LL347, p < 0.05; TPT vs. compound 13-1, p < 0.05). The tumor reduction value induced by compound LL344, however, was not statistically different from other compounds (Figure 4A). Moreover, the reduction induced by dual inhibitors was more enhanced than by the zosuquidar and Ko143 mixture, although there was no statistical difference (Figure 4B). In addition, the experimental mice did not show any notable change in their body weight during the treatment period (Figure 4C,D).

3.4. Effects of Excipients on P-gp and BCRP Dual Inhibition In Vitro and In Vivo

We investigated the effects of the modified Taxol® formulation used in the present study on TPT absorption after P-gp and BCRP inhibition (Figure 5). The effect of each excipient—Cremophor® EL, Tween® 80, and PEG 400— in the formulation on TPT accumulation was monitored in vitro (Figure 5A). The working concentration of each excipient—1.00%, 0.10%, and 1.25%, respectively— caused no significant cytotoxicity (over 90% survival rate). Cremophor® EL and Tween® 80 considerably increased TPT accumulation compared to the TPT control in P-gp-overexpressing cells, while all excipients slightly induced TPT accumulation in BCRP-overexpressing cells (Figure 5A). A significant increase in TPT accumulation was observed for Cremophor® EL in ADR cells (1.7-fold, p < 0.05) and for Tween® 80 in MX100 cells (1.5-fold, p < 0.01) only. When TPT in the modified Taxol® formulation was orally administered to rats, Cmax (approximately 3.4-fold, p < 0.01) and AUCINF (approximately 3.9-fold, p < 0.01) of TPT were remarkably enhanced, and Vd/F and Clt/F of the drug were substantially diminished to 27% (p < 0.01) and 24.9% (p < 0.01), respectively, as compared to those observed with TPT dissolved in saline (Figure 5B and Table 2). The improvement of oral TPT BA by this formulation (Table 2) was approximately 1.9~2.7-fold higher than that by the dual inhibitors (Table 1).

4. Discussion

Our laboratory’s research is focused on the development of more effective and less toxic modulators of efflux transporters to overcome the limitations of third-generation P-gp inhibitors, which have failed in the clinic [14,16]. Our previous studies concentrated on the search for novel P-gp inhibitors derived from various natural sources and on the understanding of their in vitro and in vivo effects on the PK profiles of potential anticancer drugs (P-gp substrates) [27,28,29,30,31,32] as therapeutic alternatives to third-generation P-gp inhibitors. In the present study, we investigated the potential for fourth-generation inhibition by studying compounds derived from natural sources/derivatives that were dual inhibitors targeting both P-gp and BCRP. Therefore, benzoxanthone derivatives (2 and 3) [30], coumarin derivatives (LL344 and LL347) [27], and a modified xanthone derivative (13-1) were selected from the compounds showing P-gp inhibitory activity in DNR (P-gp substrate) accumulation and efflux studies, as well as ATPase activity analysis. All the selected derivatives increased DNR accumulation in the resistant cells by over two-fold compared to DNR-only treatment [27,30] (Figure 2A). In addition, we used low working concentrations of the compounds in vitro (Table S1) and in vivo (2 mg/kg) to minimize their toxicity in the present study.
The BCRP inhibitory activity of these selected P-gp inhibitors was monitored in TPT accumulation and TPT-induced cytotoxicity experiments. The in vitro results showed that the derivatives were more effective as BCRP inhibitors than as P-gp inhibitors (Figure 2B,C). However, TPT, a substrate of P-gp and BCRP, is known to possess higher affinity for BCRP [23,37], which was confirmed by using zosuquidar and Ko143, inhibitors specific for P-gp and BCRP, respectively (Figure 1B). The BCRP-dependent pattern of TPT was also confirmed by long-term treatment with various inhibitors targeting P-gp or/and BCRP in P-gp and BCRP overexpressing cells (Figure S4A). In contrast, the results of cancer cell death induced by other P-gp/BCRP substrate drugs (MX, DNR) were different from the data of TPT (Figure S4B,C). Therefore, five of the derivatives were selected for in vivo investigation as P-gp/BCRP dual inhibitors. Of note, these five selected derivatives seemed to modulate the function of both transporters without changing their protein levels (Figure 2D).
Among the dual inhibitor candidates, compounds derived from benzoxanthone (2, 205.7 ± 86.7% and 3, RB: 168.2 ± 70.5%), coumarin (LL344, RB: 161.6 ± 85.2%), and xanthone (13-1, RB: 207.2 ± 99.4%) showed a greater enhancement of oral TPT BA (Table 1) and multiple-dose TPT-induced tumor growth reduction (Figure 4A,B). This tumor growth reduction by the dual inhibitors was considered the result of the increased oral TPT BA (Table 1), although species-related differences (mouse vs. rat) could also play a role.
The enhancement in TPT BA and AUC values after co-administration with the dual inhibitor candidates (2 mg/kg) can be explained by alterations in elimination rather than in absorption, based on the reduction in Clt/F with no significant difference in Cmax values. Interestingly, the modified Taxol® formulation significantly enhanced TPT absorption and decreased TPT elimination (Table 2). A moderate decrease in Clt/F of TPT induced by the dual inhibitor candidates to 54.3~72.9% was also observed when the P-gp specific inhibitor (zosuquidar, 25 mg/kg [37]) and the BCRP-specific inhibitor (Ko143, 10 mg/kg [37]) were co-administered with TPT (57.4% and 45.4%, respectively) (Table S2). Meanwhile, the BCRP-specific inhibitor caused not only a delay in elimination, but also enhanced absorption (>two-fold) (Table S2). In our previous study, silymarin (10 mg/kg), a P-gp inhibitor, simultaneously decreased the Vd/F and Clt/F of PTX and increased the Cmax value of PTX [38].
TPT elimination is mainly preceded by the hydrolysis of its lactone ring, converting to a ring-opened carboxylate form at physiological pH [22]. However, we did not take the pH change induced by a single and low dose of the dual inhibitor candidates (2 mg/kg) into consideration. Thus, we postulate that any alteration in TPT metabolism by the dual inhibitor candidates could be the reason for the reduced Clt/F. Initially, we speculated that CYP3A4 enzyme was involved in TPT metabolism, as: (1) the TPT metabolite (N-desmethyl form) has been reported to be the product of CYP3A metabolism [22]; (2) the enzyme is mainly present in the GI tract [39] as well as the hepatic tissue [40]; and (3) a single and low dose of the dual inhibitor candidates may not induce a severe impairment of liver or kidney function in rats. If the dual inhibitor candidates increased CYP3A4 activity in the GI tract, this could have increased TPT metabolism when TPT was absorbed through the GI tract. However, no relationship was observed between CYP3A4 activity and the dual inhibitor candidates with respect to TPT metabolism (Figure S5). According to GlaxoSmithKline, TPT does not alter the in vitro activity of CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A, or CYP4A [41]. CYP3A4 may not be involved in the decrease in Clt/F of TPT observed in the present study. This implies that there may be another metabolic pathway that is inhibited by these dual inhibitor candidates, or another unidentified reason responsible for the BCRP inhibition-dependent decrease in oral TPT clearance.
Furthermore, to our knowledge, this is the first report of dual target inhibition of anticancer drug efflux transporters by formulation excipients. We developed the formulation with several excipients reported to have inhibitory activity toward P-gp or BCRP. The inhibitory effects of Cremophor® EL on P-gp or/and BCRP function are well known, and the effects of Tween® 80 on P-gp, but not BCRP, have been well established [19]. In order to examine the effect of excipients on P-gp/BCRP dual inhibition, we developed the TPT formulation based on the Taxol® formulation with the addition of Tween® 80 and PEG 400 and the replacement of ethanol with saline for in vivo study. TPT dissolved very well in the developed formulation. We confirmed the inhibitory effects of these two surfactants on both efflux transporters in our study (Figure 5A). In particular, Tween® 80 was found to be an efficient inhibitor of BCRP function, as evidenced by the increased TPT accumulation in BCRP-overexpressing cells (Figure 5A). In vivo, Tween® 80 (1–2.5%) improved oral TPT BA (over 1.5-fold), with an increase in Cmax and AUCINF and a significant decrease in Vd/F (Table S3). When all excipients were mixed properly, the modified Taxol® formulation (22.5% Cremophor® EL, 4.5% PEG 400, 0.45% Tween® 80, 62.55% saline, and 10% DMSO) played an important role in the enhancement of oral TPT BA (approximately four-fold), with a significant increase in drug absorption and exposure in the body (Figure 5B and Table 2). Excipients in the formulation showed stronger effects on TPT absorption by inhibiting P-gp and BCRP function in the GI tract [6] when the anticancer drug passed through the tract (Tmax ~1 h in Table 2) and on TPT clearance by dual inhibition in the elimination organs [6]. DMSO, which was used for dissolving the dual inhibitor candidates and Ko143, has not been reported to have any effect on the target efflux transporters. The TPT formulation composed with the surfactants which inhibited P-gp/BCRP function increased oral TPT BA much higher than the dual transporter inhibitors (compounds) in the present study. This highlights the promising drug formulation-based strategy to overcome MDR in chemotherapy.

5. Conclusions

In this study, the successful enhancement of oral TPT BA by P-gp/BCRP dual inhibition was demonstrated. The results showed the enhanced formulation-induced TPT absorption, and the retarded formulation- and dual inhibitor-mediated TPT elimination. P-gp inhibitors, derived from natural compounds and reported in our previous publications, were confirmed as dual inhibitors targeting BCRP as well. The dual inhibitors increased TPT accumulation in resistant cells overexpressing P-gp or BCRP, and improved oral TPT BA in rats, showing greater inhibition of BCRP. The dual inhibitors significantly enhanced tumor growth inhibition following the administration of a low dose of oral TPT in xenograft mice. Moreover, the modified Taxol® formulation (22.5% Cremophor® EL, 4.5% PEG 400, 0.45% Tween® 80, 62.55% saline, and 10% DMSO) also significantly enhanced oral TPT BA. The combination of the dual-target inhibition of anticancer drug efflux transporters, natural compound derivatives, and drug formulation can used to overcome the limitations of third generation P-gp inhibitors.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/pharmaceutics13040559/s1, Figures S1‒S5: The structure of P-gp inhibitors; P-gp or/and BCRP substrate anticancer drug accumulation analysis; In vitro study in human colon cancer cell, HT29; The effects of different anticancer drugs on cancer cell death; CYP3A4 activation assay with P-gp and BCRP dual inhibitor candidates in vitro. Tables S1‒S3: Working concentration of dual inhibitors in vitro; Effects of P-gp and/or BCRP inhibitor on PK parameters of TPT following oral administration in rats; Effects of Tween 80 on PK parameters of TPT following oral administration in rats.

Author Contributions

Conceptualization, J.L. and H.-J.L.; Methodology, J.L., K.L., Y.N., S.-Y.J. and H.-J.L.; Formal Analysis, S.-Y.J., A.R.O., J.L. and H.-J.L.; Investigation, N.-Y.K., J.L., J.K., A.S., R.N., S.-Y.J., A.R.O. and J.-H.S.; Resources, A.S., R.N., J.-H.S., K.L. and Y.N.; Data Curation, J.L.; Writing—Original Draft Preparation, J.L., J.K. and H.-J.L.; Writing—Review and Editing, J.L., J.K. and H.-J.L.; Visualization, J.L., N.-Y.K. and J.K.; Supervision, H.-J.L.; Project Administration, H.-J.L.; Funding Acquisition, H.-J.L., K.L. and J.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (2020R1A2B5B01002489 (H.-J.L.) and 2018R1A5A2023127 (K.L.)). J.L. was supported by a Research Professor Grant 2021 of Ewha Womans University.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of EWHA WOMANS UNIVERSITY (No. 2019-19-002, 11 January 2019 for the PK study; No. 2016-16-062, 7 December 2016; and No. 2018-18-072 29 December 2018 for the xenograft study).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are available in a publicly accessible repository.

Acknowledgments

We are thankful to M.E. Morris (University of Buffalo, New York, USA) and U. Schumacher (University Medical Center of Hamburg-Eppendorf, Hamburg, Germany) for providing the MCF-7/ADR and MCF-7/MX100 cell lines, and HT29 and HT29/MDR cell lines, respectively.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Trowitzsch, S.; Tampe, R. ABC transporters in dynamic macromolecular assemblies. J. Mol. Biol. 2018, 430, 4481–4495. [Google Scholar]
  2. Liu, X. ABC Family Transporters. Adv. Exp. Med. Biol 2019, 1141, 13–100. [Google Scholar]
  3. Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 2018, 18, 452–464. [Google Scholar]
  4. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta Biomembr. 1976, 455, 152–162. [Google Scholar]
  5. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665–15670. [Google Scholar]
  6. Dei, S.; Braconi, L.; Romanelli, M.N.; Teodori, E. Recent advances in the search of BCRP-and dual P-gp/BCRP-based multidrug resistance modulators. Cancer Drug Resist. 2019, 2, 710–743. [Google Scholar]
  7. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11, 1156–1166. [Google Scholar]
  8. Durmus, S.; Hendrikx, J.J.; Schinkel, A.H. Apical ABC transporters and cancer chemotherapeutic drug disposition. Adv. Cancer Res. 2015, 125, 1–41. [Google Scholar]
  9. Chen, Z.; Shi, T.; Zhang, L.; Zhu, P.; Deng, M.; Huang, C.; Hu, T.; Jiang, L.; Li, J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016, 370, 153–164. [Google Scholar]
  10. Hee Choi, Y.; Yu, A.-M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Currt. Pharm. Des. 2014, 20, 793–807. [Google Scholar]
  11. U.S. Food and Drug Administration, In Vitro Drug Interaction Studies-Cytochrome P450 Enzymes- and Transporter-Mediated Drug Interactions Guidance for Industry. Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions (accessed on 24 August 2020).
  12. Palmeira, A.; Sousa, E.; H. Vasconcelos, M.; M. Pinto, M. Three decades of P-gp inhibitors: Skimming through several generations and scaffolds. Curr. Med. Chem. 2012, 19, 1946–2025. [Google Scholar]
  13. Chung, F.S.; Santiago, J.S.; De Jesus, M.F.M.; Trinidad, C.V.; See, M.F.E. Disrupting P-glycoprotein function in clinical settings: What can we learn from the fundamental aspects of this transporter? Am. J. Cancer Res. 2016, 6, 1583. [Google Scholar]
  14. Waghray, D.; Zhang, Q. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J. Med. Chem. 2018, 61, 5108–5121. [Google Scholar]
  15. Peña-Solórzano, D.; Stark, S.A.; König, B.; Sierra, C.A.; Ochoa-Puentes, C. ABCG2/BCRP: Specific and nonspecific modulators. Med. Res. Rev. 2017, 37, 987–1050. [Google Scholar]
  16. Dong, J.; Qin, Z.; Zhang, W.D.; Cheng, G.; Yehuda, A.G.; Ashby, C.R., Jr.; Chen, Z.S.; Cheng, X.D.; Qin, J.J. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resist. Updat. 2020, 49, 100681. [Google Scholar]
  17. De Gooijer, M.C.; de Vries, N.A.; Buckle, T.; Buil, L.C.; Beijnen, J.H.; Boogerd, W.; van Tellingen, O. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia 2018, 20, 710–720. [Google Scholar]
  18. Wu, C.-P.; Lusvarghi, S.; Wang, J.-C.; Hsiao, S.-H.; Huang, Y.-H.; Hung, T.-H.; Ambudkar, S.V. The selective class IIa histone deacetylase inhibitor TMP195 resensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. Int. J. Mol. Sci. 2019, 21, 238. [Google Scholar]
  19. Al-Ali, A.A.A.; Nielsen, R.B.; Steffansen, B.; Holm, R.; Nielsen, C.U. Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption. Int. J. Pharm. 2019, 566, 410–433. [Google Scholar]
  20. Zou, L.; Pottel, J.; Khuri, N.; Ngo, H.X.; Ni, Z.; Tsakalozou, E.; Warren, M.S.; Huang, Y.; Shoichet, B.K.; Giacomini, K.M. Interactions of oral molecular excipients with breast cancer resistance protein, BCRP. Mol. Pharm. 2020, 17, 748–756. [Google Scholar]
  21. Saraf, S.; Jain, A.; Hurkat, P.; Jain, S.K. Topotecan liposomes: A visit from a molecular to a therapeutic platform. Crit Rev. Ther Drug Carr. Syst. 2016, 33, 401–432. [Google Scholar]
  22. Herben, V.M.; ten Bokkel Huinink, W.W.; Beijnen, J.H. Clinical pharmacokinetics of topotecan. Clin. Pharm. 1996, 31, 85–102. [Google Scholar]
  23. Breedveld, P.; Beijnen, J.H.; Schellens, J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 2006, 27, 17–24. [Google Scholar]
  24. Yamagata, T.; Kusuhara, H.; Morishita, M.; Takayama, K.; Benameur, H.; Sugiyama, Y. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab. Dispos. 2007, 35, 1142–1148. [Google Scholar]
  25. Shen, J.; Carcaboso, A.M.; Hubbard, K.E.; Tagen, M.; Wynn, H.G.; Panetta, J.C.; Waters, C.M.; Elmeliegy, M.A.; Stewart, C.F. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res. 2009, 69, 5885–5892. [Google Scholar]
  26. Ling, X.; Liu, X.; Zhong, K.; Smith, N.; Prey, J.; Li, F. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am. J. Transl. Res. 2015, 7, 1765–1781. [Google Scholar]
  27. Lee, K.; Chae, S.W.; Xia, Y.; Kim, N.H.; Kim, H.J.; Rhie, S.; Lee, H.J. Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel. Eur. J. Pharmacol. 2014, 723, 381–388. [Google Scholar]
  28. Chae, S.W.; Han, A.R.; Park, J.H.; Rhie, J.Y.; Lim, H.J.; Seo, E.K.; Lee, H.J. In vitro and in vivo evaluation of phenylbutenoid dimers as inhibitors of P-glycoprotein. J. Nat. Prod. 2013, 76, 2277–2281. [Google Scholar]
  29. Chae, S.W.; Woo, S.; Park, J.H.; Kwon, Y.; Na, Y.; Lee, H.J. Xanthone analogues as potent modulators of intestinal P-glycoprotein. Eur. J. Med. Chem. 2015, 93, 237–245. [Google Scholar]
  30. Chae, S.W.; Lee, J.; Park, J.H.; Kwon, Y.; Na, Y.; Lee, H.J. Intestinal P-glycoprotein inhibitors, benzoxanthone analogues. J. Pharm. Pharmacol 2018, 70, 234–241. [Google Scholar]
  31. Lee, J.; Chae, S.W.; Oh, A.R.; Yoo, J.H.; Park Choo, H.Y.; Rhie, S.J.; Lee, H.J. Effects of piperazine derivative on paclitaxel pharmacokinetics. Pharmaceutics 2019, 11, 23–31. [Google Scholar]
  32. Lee, J.; Chae, S.W.; Ma, L.; Lim, S.Y.; Alnajjar, S.; Park Choo, H.Y.; Lee, H.J.; Rhie, S.J. Pharmacokinetic ateration of paclitaxel by ferulic acid derivative. Pharmaceutics 2019, 11, 593–603. [Google Scholar]
  33. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107–1112. [Google Scholar]
  34. US Department of Health and Human Services, Food and Drug Administration Center, Bioanalytical Method Validation Guidance for Industry. Available online: https://www.fda.dov/media/70858/download (accessed on 24 August 2020).
  35. Hu, T.; Li, Z.; Gao, C.-Y.; Cho, C.H. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J. Gastroenterol 2016, 22, 6876–6889. [Google Scholar]
  36. Takano, M.; Yumoto, R.; Murakmi, T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 2006, 109, 137–161. [Google Scholar]
  37. Matsuda, Y.; Konno, Y.; Hashimoto, T.; Nagai, M.; Taguchi, T.; Satsukawa, M.; Yamashita, S. In Vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein–cannulated rats. Drug Metab. Dispos. 2013, 41, 1514–1521. [Google Scholar]
  38. Park, J.H.; Park, J.H.; Hur, H.J.; Woo, J.S.; Lee, H.J. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur. J. Pharm. Sci. 2012, 45, 296–301. [Google Scholar]
  39. Thelen, K.; Dressman, J.B. Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol. 2009, 61, 541–558. [Google Scholar]
  40. Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013, 138, 103–141. [Google Scholar]
  41. Prescribing Information of HYCAMTIN® (Topotecan) Capsule. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020981lbl.pdf (accessed on 12 August 2020).
Pharmaceutics 13 00559 g001 550
Figure 1. P-gp- and BCRP-overexpressing in vitro system. (A) Western blotting analysis using anti-P-gp and anti-BCRP antibodies in ADR and MX100 cell lines versus the MCF-7 cell line. (B) TPT (200 μM) accumulation after co-treatment with zosuquidar (1 μM), Ko143 (1 μM), and the combination of both (1 μM each) in ADR and MX100 cells. P-gp: P-glycoprotein; BCRP: breast cancer resistance protein; TPT: topotecan; ZSQ: zosuquidar; ZSQ/Ko: the combination of zosuquidar and Ko143. ** p < 0.01; *** p < 0.001.
Figure 1. P-gp- and BCRP-overexpressing in vitro system. (A) Western blotting analysis using anti-P-gp and anti-BCRP antibodies in ADR and MX100 cell lines versus the MCF-7 cell line. (B) TPT (200 μM) accumulation after co-treatment with zosuquidar (1 μM), Ko143 (1 μM), and the combination of both (1 μM each) in ADR and MX100 cells. P-gp: P-glycoprotein; BCRP: breast cancer resistance protein; TPT: topotecan; ZSQ: zosuquidar; ZSQ/Ko: the combination of zosuquidar and Ko143. ** p < 0.01; *** p < 0.001.
Pharmaceutics 13 00559 g001
Pharmaceutics 13 00559 g002 550
Figure 2. Decreased TPT efflux by P-gp inhibitors. (A) DNR accumulation after co-treatment with compound 13-1 in ADR cells. (B) TPT accumulation after co-treatment with compounds 2, 3, LL344, LL347, and 13-1 in ADR and MX100 cells. (C) Cell survival analysis after TPT co-treatment with the compounds (48 h) in ADR and MX100 cells. (D) Western blotting analysis of P-gp and BCRP protein expression levels during long-term treatment with compounds (48 h). Cntl: control; #2: compound 2; #3: compound 3; LL344: compound LL344; LL347: compound LL347; #13-1: compound 13-1; DNR: daunorubicin. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Figure 2. Decreased TPT efflux by P-gp inhibitors. (A) DNR accumulation after co-treatment with compound 13-1 in ADR cells. (B) TPT accumulation after co-treatment with compounds 2, 3, LL344, LL347, and 13-1 in ADR and MX100 cells. (C) Cell survival analysis after TPT co-treatment with the compounds (48 h) in ADR and MX100 cells. (D) Western blotting analysis of P-gp and BCRP protein expression levels during long-term treatment with compounds (48 h). Cntl: control; #2: compound 2; #3: compound 3; LL344: compound LL344; LL347: compound LL347; #13-1: compound 13-1; DNR: daunorubicin. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Pharmaceutics 13 00559 g002
Pharmaceutics 13 00559 g003 550
Figure 3. Mean plasma concentration–time profiles following the oral co-administration of TPT with P-gp and BCRP dual inhibitor candidates to rats. (A) Benzoxanthone and xanthone derivatives and (B) coumarin derivatives. Bars represent S.D. (n = 4–6). TPT (20 mg/kg, PO) was orally administered alone or with each compound (2 mg/kg) to rats. S.D., standard deviation; PO, per oral.
Figure 3. Mean plasma concentration–time profiles following the oral co-administration of TPT with P-gp and BCRP dual inhibitor candidates to rats. (A) Benzoxanthone and xanthone derivatives and (B) coumarin derivatives. Bars represent S.D. (n = 4–6). TPT (20 mg/kg, PO) was orally administered alone or with each compound (2 mg/kg) to rats. S.D., standard deviation; PO, per oral.
Pharmaceutics 13 00559 g003
Pharmaceutics 13 00559 g004 550
Figure 4. Reduction in tumor growth by oral TPT co-administration with the dual inhibitor candidates. (A) Change in tumor volume after co-treatment of TPT with compounds 3, LL344, and 13-1 versus TPT-only and vehicle-only controls twice a week (n = 5–7). (B) Change in tumor volume after co-treatment of TPT with compounds 2 and LL347 versus TPT-only, vehicle-only, and positive controls (co-treatment with the combination of zosuquidar and Ko143) twice a week (n = 5). (C) Change in body weight after treatment scheme described in A. (D) Change in body weight after treatment scheme described in B. Bars represent S.E.M. Cntl: vehicle-treated control; TPT: 1 mg/kg; each compound: 2 mg/kg; ZSQ/Ko: the mixture of zosuquidar and Ko143, 2 mg/kg each. * p < 0.05; ** p < 0.01.
Figure 4. Reduction in tumor growth by oral TPT co-administration with the dual inhibitor candidates. (A) Change in tumor volume after co-treatment of TPT with compounds 3, LL344, and 13-1 versus TPT-only and vehicle-only controls twice a week (n = 5–7). (B) Change in tumor volume after co-treatment of TPT with compounds 2 and LL347 versus TPT-only, vehicle-only, and positive controls (co-treatment with the combination of zosuquidar and Ko143) twice a week (n = 5). (C) Change in body weight after treatment scheme described in A. (D) Change in body weight after treatment scheme described in B. Bars represent S.E.M. Cntl: vehicle-treated control; TPT: 1 mg/kg; each compound: 2 mg/kg; ZSQ/Ko: the mixture of zosuquidar and Ko143, 2 mg/kg each. * p < 0.05; ** p < 0.01.
Pharmaceutics 13 00559 g004
Pharmaceutics 13 00559 g005 550
Figure 5. Effects of excipients on TPT accumulation and absorption. (A) TPT accumulation in the presence and absence of each excipient in P-gp- or BCRP-overexpressing cell lines. (B) Mean plasma concentration–time profiles of TPT (20 mg/kg) following the oral administration of different formulations of TPT to rats. Bars represent S.D. (n = 6-7). * p < 0.05; ** p < 0.01.
Figure 5. Effects of excipients on TPT accumulation and absorption. (A) TPT accumulation in the presence and absence of each excipient in P-gp- or BCRP-overexpressing cell lines. (B) Mean plasma concentration–time profiles of TPT (20 mg/kg) following the oral administration of different formulations of TPT to rats. Bars represent S.D. (n = 6-7). * p < 0.05; ** p < 0.01.
Pharmaceutics 13 00559 g005
Table
Table 1. Pharmacokinetic parameters of TPT following oral administration with or without P-gp and BCRP dual inhibitor candidates.
Table 1. Pharmacokinetic parameters of TPT following oral administration with or without P-gp and BCRP dual inhibitor candidates.
PK ParametersOral Administration
TPT#2 + TPT#3 + TPTLL344 + TPTLL347 + TPT#13-1 + TPT
Cmax (μg/mL)0.727 ± 0.2651.14 ± 0.2151.02 ± 0.2660.832 ± 0.2660.604 ± 0.1890.938 ± 0.375
Tmax (h)(0.5–1.0))(0.5–1.0)(0.5–1.0)(0.5–1.0)(0.5–2.0)(0.25–2.0)
AUCINF (μg·h/mL)2.36 ± 0.5434.86 ± 2.023.97 ± 1.713.82 ± 2.013.33 ± 0.3654.90 ± 2.63
t1/2 (h)3.39 ± 1.094.88 ± 2.704.06 ± 2.414.40 ± 1.915.95 ± 1.636.80 ± 5.61
Vd/F (L)42.1 ± 14.129.9 ± 14.827.2 ± 8.9337.2 ± 16.651.1 ± 11.141.3 ± 30.3
Clt/F (L/h)8.94 ± 2.584.85 ± 2.226.52 ± 4.716.34 ± 3.016.06 ± 0.6715.14 ± 2.87
RB (%)100.0205.7 ± 86.7168.2 ± 70.5161.6 ± 85.2140.8 ± 15.4207.2 ± 99.4
#2: compound 2; #3: compound 3; LL344: compound LL344; LL347: compound LL347; #13-1: compound 13-1.
Table
Table 2. Pharmacokinetic parameters obtained following the oral administration of different formulations of TPT to rats.
Table 2. Pharmacokinetic parameters obtained following the oral administration of different formulations of TPT to rats.
PK ParametersOral Administration
TPT in SalineTPT in Modified Taxol® Formulation 1
Cmax (μg/mL)0.214 ± 0.1410.727 ± 0.265 **
Tmax (h)(0.05–0.5)(0.5–1.0)
AUCINF (μg·h/mL)0.611 ± 0.2092.36 ± 0.543 **
t1/2 (h)3.06 ± 1.343.39 ± 1.09
Vd/F (L)155.2 ± 79.942.1 ± 14.1 **
Clt/F (L/h)35.9 ± 11.48.94 ± 2.58 **
RB (%)100.0387.0 ± 88.9
** p < 0.01. 1 22.5% Cremophor® EL; 4.5% PEG 400; 0.45% Tween® 80; 62.55% isotonic saline solution; 10% DMSO.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lee, J.; Kang, J.; Kwon, N.-Y.; Sivaraman, A.; Naik, R.; Jin, S.-Y.; Oh, A.R.; Shin, J.-H.; Na, Y.; Lee, K.; et al. Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents. Pharmaceutics 2021, 13, 559. https://doi.org/10.3390/pharmaceutics13040559

AMA Style

Lee J, Kang J, Kwon N-Y, Sivaraman A, Naik R, Jin S-Y, Oh AR, Shin J-H, Na Y, Lee K, et al. Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents. Pharmaceutics. 2021; 13(4):559. https://doi.org/10.3390/pharmaceutics13040559

Chicago/Turabian Style

Lee, Jaeok, Jiyeon Kang, Na-Yun Kwon, Aneesh Sivaraman, Ravi Naik, So-Young Jin, A. Reum Oh, Jae-Ho Shin, Younghwa Na, Kyeong Lee, and et al. 2021. "Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents" Pharmaceutics 13, no. 4: 559. https://doi.org/10.3390/pharmaceutics13040559

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop